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Abstract 
Background: Literatures reported that poor sleep complaints were associated with a great deal of health outcomes. 
However, there are few studies on the association of poor sleep complaints with diabetic vascular complications.
Methods: Aiming on the association, a cross‑sectional survey was conducted among 1220 diabetic patients in this 
study. Poor sleep complaints were composed of difficulty falling asleep, early final awakening, short sleep and long 
sleep. The diabetic vascular complications involved in the study were diagnosed according to the Standards of Medi‑
cal Care in Diabetes (ADA 2016).
Results: Our findings indicated that short sleep remained independently associated with diabetic kidney disease 
(DKD) (OR > 1, P < 0.05) after the adjustments; long sleep independently associated with diabetic retinopathy (DR) 
(OR > 1, P < 0.05); early final awakening and short sleep independently associated with cardiovascular disease (OR > 1, 
P < 0.05); short sleep independently associated with peripheral arterial disease (OR > 1, P < 0.05); there was no asso‑
ciation between poor sleep complaints and neuropathy (P > 0.05).
Conclusions: The study suggests that the poor sleep complaints were distinguishably associated with diabetic vas‑
cular complications. Clinicians should take poor sleep complaints into account in diabetes treatment.
Keywords: Poor sleep complaints, Diabetic kidney disease (DKD), Neuropathy, Diabetic retinopathy (DR), 
Cardiovascular disease (CVD), Peripheral arterial disease (PAD)
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Background
In recent years, evidences from experimental and epide-
miologic studies have demonstrated that poor sleep qual-
ity is associated with a great deal of health outcomes such 
as diabetes, cardiovascular disease, hypertension and 
obesity [1–4]. Poor sleep or sleep disturbances are well-
known symptoms in type 2 diabetes, which have been 
noted by many researchers [5–7]. Diabetic vascular com-
plications covered macrovascular complications includ-
ing cardiovascular disease (CVD), peripheral arterial 
disease (PAD) and stroke, and microvascular complica-
tions such as diabetic kidney diseases (DKD), neuropathy 
and retinopathy [8]. Some literatures reported that sleep 
disturbances or obstructive sleep apnea is one of the risk 
factors causing CVD [9–11]. One study demonstrated 
that abnormal sleep patterns could influence the diabetic 
microvascular complications, in particular diabetic neu-
ropathy [12]. Another study described a novel independ-
ent association between diabetic peripheral neuropathy 
and obstructive sleep apnea (OSA) [13]. Some studies 
proposed that OSA may contribute to development of 
DKD [14, 15]. Nishimura et al. concluded that there was 
an independent relationship between severity of sleep 
disordered breathing and retinopathy in patients with 
diabetes [16]. In addition, diabetic vascular complications 
were considered to have important impact on sleep qual-
ity, especially retinopathy and neuropathy [17].
So far, most studies related to sleep disorders and dia-
betic vascular complications have focused mainly on 
OSA. There are few studies on various poor sleep com-
plaints with the complications systematically. The aim 
of the present study was to investigate the association 
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between poor sleep complaints with the diabetic vascu-
lar complications in a population-based cross-sectional 
study.
Methods
Materials and subjects
We conducted a population-based cross-sectional study 
in Chinese adults with type 2 diabetes. Patients were 
recruited between January 2013 and January 2016 from 
Metabolic Diseases Hospital of Tianjin Medical Uni-
versity. Inclusion criterion was those patients who were 
diagnosed with type 2 diabetes according to the 1999 
WHO diagnostic criteria for diabetes. Exclusion crite-
ria included type 1 diabetes mellitus, pre-diabetes, dia-
betes with snoring, acute complications, severe kidney 
dysfunction, decompensated liver cirrhosis, heart fail-
ure with an ejection fraction  <30% or NYHA classifica-
tion  >II. The diseases affecting sleep quality were also 
excluded, including restless leg syndrome, pruritic skin 
disorders, mental illness and thyroid disease. Consent 
was obtained and this study design was approved by the 
local ethics committee and was in accordance with the 
Declaration of Helsinki. Demographic data such as age 
and gender were collected and physical examinations 
including body mass index (BMI) and blood pressure 
were performed in the subjects. Glycosylated hemo-
globin (HbA1C) was measured using standard high-per-
formance liquid chromatography.
Definitions
The poor sleep complaints included difficulty falling 
asleep, early final awakening, short sleep and long sleep 
in this study. The frequency of difficulty falling asleep 
more than three times a week was defined difficulty fall-
ing asleep. The definition of early final awakening was 
consistent with the above. Sleep duration <6 h/night was 
defined as short sleep, and sleep duration >9 h/night was 
defined as long sleep.
Diabetic vascular complications covered microangi-
opathy such as DKD, DR and diabetic neuropathy, and 
macroangiopathy such as CVD and lower extremity PAD. 
DKD was defined as the presence of albuminuria [urinary 
levels of 24-h microalbumin (UMA) >30 mg/24 h] and/or 
an estimated glomerular filtration rate (eGFR)  <60  mL/
min/1.73  m2 [15]. eGFR was calculated using the four-
variable Modification of Diet in Renal Disease equation 
(MDRD). Diabetic neuropathy diagnosis based on the 
results of nerve conduction study, which is a reliable, 
accurate and sensitive method to evaluate peripheral 
nerve function [18]. Patients’ clinical symptoms included 
hyperesthesia, paresthesia, motor weakness or polyra-
diculopathy [17]. DR was determined by experienced 
ophthalmologists using dilated indirect ophthalmoscopy 
or retinal photographs. Retinopathy was defined as at 
least two microaneurysms and/or retinal hemorrhage 
and/or other signs of retinal damage [19]. In this study, 
CVD includes coronary artery disease, hypertensive 
heart disease, and congestive heart failure (an ejection 
fraction ≥30% or NYHA classification ≤II) [9]. PAD was 
diagnosed according to the four typical clinical staging 
of symptoms, including lower extremity arterial pulses 
weakening or disappearing found in physical examina-
tion and change in lower extremity nutrition disorder or 
pale, combined with related risk factors such as diabetes, 
dyslipidemia, hypertension, age and so on. Patients with 
PAD were confirmed to have different degree of lower 
extremity artery occlusion using Vascular Ultrasonog-
raphy. Dyslipidemia was defined that TG, LDL or VLDL 
was higher than the upper limit of normal or HDL was 
lower than the lower limit of normal.
Statistical analysis
All parametrically distributed date are expressed as 
mean  ±  standard deviation (SD). Categorical variables 
are shown as frequencies; Chi square test was used to 
analyze these variables. Two-sided values of P  <  0.05 
were considered as statistically significant. Multivariate 
logistic regression analysis was performed to assess the 
association between poor sleep complaints with vascular 
complications using odds ratio (OR) and 95% confidence 
intervals (CI). We adjusted for major confounding factors 
expected to affect these relationships (i.e. gender, age, 
smoking history, BMI, SBP, duration of diabetes, HbA1C 
and dyslipidemia). SPSS (Statistical Package for Social 
Sciences) for Windows 18.0 program was used for statis-
tical analysis.
Results
Table  1 shows the association of poor sleep com-
plaints and baseline characteristics with complica-
tions in participants with diabetes. The frequency of 
early final awakening and short sleep were higher in 
patients with DKD (56.7 vs. 47.7%, P =  0.005; 51.7 vs. 
45.3%, P = 0.043). The frequency of early final awaken-
ing and long sleep were higher in patients with DR (55.6 
vs. 47.7%, P  =  0.011; 6.0 vs.2.2%, P  =  0.002). Subjects 
with diabetic neuropathy had higher prevalence of dif-
ficulty falling asleep (30.3 vs. 24.0%, P  =  0.020), early 
final awakening (54.3 vs. 43.7%, P  =  0.000) and short 
sleep (49.5 vs. 43.2%, P =  0.037), respectively. The fre-
quency of early final awakening and short sleep were 
higher in the diabetic patients with CVD (56.4 vs. 41.5%, 
P =  0.000; 53.0 vs. 38.6%, P =  0.000, respectively). The 
frequency of early final awakening and short sleep were 
higher in the diabetic patients with PAD (52.5 vs. 46.0%, 
P = 0.043; 49.5 vs. 40.9%, P = 0.007). The patients with 
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DKD had higher BMI, SBP, DBP and HbA1C (P < 0.05), 
longer diabetes duration (P  <  0.05), and higher rate of 
male (60.9 vs. 51.9%, P < 0.05) compared to those with-
out DKD. The patients with DR were older than those 
without DR, and had higher rate of female (51.7 vs. 
42.0%, P  <  0.05), longer diabetes duration (P  <  0.05), 
higher SBP (P  <  0.05). The patients with neuropathy 
were older (P  <  0.05), and had longer diabetes dura-
tion (P < 0.05), higher SBP (P < 0.05) and lower HbA1C 
(P  <  0.05), compared to those without neuropathy. The 
patients with CVD were older (P < 0.05), and had higher 
BMI, SBP (P  <  0.05), lower HbA1C (P  <  0.05), longer 
diabetes duration (P  <  0.05) compared to those with-
out CVD. The patients with PAD were older (P < 0.05), 
and higher rate of male (56.2 vs. 48.4%, P < 0.05), longer 
diabetes duration (P  <  0.05), lower HbA1C (P  <  0.05) 
compared to those without PAD.
Table 2 describes the effect of the demographics (gen-
der, age and BMI) on the poor sleep complaints. The 
complaints were individually saved as dependent vari-
able, and the demographics were saved as independ-
ent variables. Older patients were more likely to have 
these complaints, difficulty fall asleep [OR 1.015, 95% CI 
(1.002–1.027) P = 0.020], early awake [OR 1.045, 95% CI 
(1.032–1.057) P = 0.000] and short sleep [OR 1.015, 95% 
CI (1.004–1.026) P = 0.006]. The female were more vul-
nerable to have difficulty fall asleep [OR 1.764, 95% CI 
(1.350–2.307) P  =  0.000]. The fatter participants were 
less trouble in falling asleep [OR 0.955, 95% CI (0.922–
0.990) P = 0.012].
Table 1 Associations of  poor sleep complaints and  baseline characteristics with  complications in  subjects with  type 2 
diabetes mellitus
Italics values are statistically significant
DKD diabetic kidney disease; CVD cardiovascular disease; PAD peripheral arterial disease; BMI body mass index; SBP systolic blood pressure; DBP diastolic blood 
pressure; PSQI Pittsburgh Sleep Quality Index; HbAlc glycosylated hemoglobin type A1c
Microangiopathies DKD Retinopathy Neuropathy
Absent Present P value Absent Present P value Absent Present P value
Complaints of poor sleep
 Difficulty fall asleep 232 (28.1) 98 (27.2) 0.778 208 (26.8) 124 (30.0) 0.250 110 (24.0) 224 (30.3) 0.020
 Early awake 394 (47.7) 204 (56.7) 0.005 370 (47.7) 230 (55.6) 0.011 200 (43.7) 402 (54.3) 0.000
 Short sleep <6 h 374 (45.3) 186 (51.7) 0.043 372 (47.9) 186 (44.9) 0.330 198 (43.2) 366 (49.5) 0.037
 Long sleep >9 h 22 (2.8) 18 (5.2) 0.057 16 (2.2) 24 (6.0) 0.002 16 (3.6) 24 (3.5) 1.000
 Male (%) 402 (51.9%) 212 (60.9%) 0.005 420 (58.0%) 194 (48.3%) 0.002 362 (52.5%) 258 (58.1%) 0.067
 Age (years) 56.13 ± 11.20 57.21 ± 11.63 0.149 55.75 ± 11.72 57.78 ± 10.41 0.004 52.64 ± 12.63 58.91 ± 9.63 0.000
 BMI (kg/m2) 26.17 ± 3.95 27.34 ± 3.71 0.000 26.53 ± 4.01 26.43 ± 3.77 0.690 26.59 ± 4.06 26.47 ± 3.83 0.639
 Diabetes duration 
(years)
8.18 ± 7.26 10.68 ± 7.38 0.000 7.19 ± 6.75 12.13 ± 7.54 0.000 5.48 ± 6.27 11.20 ± 7.23 0.000
 SBP (mmHg) 130.63 ± 14.01 136.06 ± 17.57 0.000 131.29 ± 14.8 134.65 ± 16.2 0.005 130.94 ± 15.4 133.15 ± 15.27 0.019
 DBP (mmHg) 80.01 ± 8.51 81.57 ± 9.75 0.007 80.42 ± 8.70 80.52 ± 9.32 0.870 80.90 ± 9.23 80.22 ± 8.19 0.212
 HbA1C (%) 8.96 ± 1.79 9.23 ± 1.70 0.021 9.05 ± 1.89 9.06 ± 1.51 0.927 9.29 ± 1.94 8.88 ± 1.62 0.000
Macroangiopathies CVD PAD
Absent Present P value Absent Present P value
Complaints of poor sleep
 Difficulty fall asleep 132 (26.8) 202 (28.8) 0.472 90 (25.6) 256 (29.5) 0.183
 Early awake 204 (41.5) 396 (56.4) 0.000 162 (46.0) 456 (52.5) 0.043
 Short sleep <6 h 190 (38.6) 372 (53.0) 0.000 144 (40.9) 430 (49.5) 0.007
 Long sleep >9 h 18 (3.9) 22 (3.3) 0.624 10 (4.1) 30 (3.4) 0.562
 Male (%) 264 (57.6%) 354 (52.7%) 0.101 118 (48.4%) 496 (56.2%) 0.030
 Age (years) 52.20 ± 11.96 59.33 ± 9.90 0.000 51.71 ± 12.95 57.79 ± 10.43 0.000
 BMI (kg/m2) 25.99 ± 3.87 26.87 ± 3.91 0.000 26.44 ± 4.12 26.51 ± 3.85 0.828
 Diabetes duration (years) 7.27 ± 6.99 10.07 ± 7.49 0.000 6.61 ± 6.40 9.61 ± 7.56 0.000
 SBP (mmHg) 129.80 ± 14.3 133.93 ± 15.5 0.000 131.93 ± 16.4 132.38 ± 15.1 0.699
 SBP (mmHg) 80.65 ± 8.52 80.35 ± 9.18 0.589 80.76 ± 9.52 80.38 ± 8.76 0.572
 HbA1C (%) 9.42 ± 1.99 8.80 ± 1.55 0.000 9.48 ± 1.98 8.93 ± 1.69 0.000
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Table  3 shows the multivariate analysis for impact of 
poor sleep complaints on diabetic complications in the 
populations (model 1). In this model, diabetic vascular 
complications were individually put into dependent vari-
ables, and poor sleep complaints were individually put 
into independent variables. We adjusted for possible fac-
tors (age, gender, duration of diabetes, BMI, SBP, HbA1C, 
smoking history and dyslipidemia) in the regression anal-
ysis. Subjects with short sleep had a higher risk of devel-
oping DKD [OR 1.317, 95% CI (1.006–1.723) P = 0.045]; 
participants with long sleep had a higher risk of devel-
oping DR [OR 3.409, 95% CI (1.671–6.995) P =  0.001]; 
the risk of CVD was higher among the subjects with 
final early awakening [OR 1.348,95% CI (1.042–1.745) 
P = 0.023] and/or short sleep [OR 1.589, 95% CI (1.232–
2.049) P  =  0.000); the risk of PAD was higher among 
the subjects with short sleep [OR 1.343, 95% CI (1.024–
1.762) P  =  0.033); after adjustment of potential con-
founders, poor sleep complaints have no association with 
the development of neuropathy (P > 0.05).
Table  4 shows the multivariate analysis for impact of 
diabetic complications on poor sleep complaints in the 
studied-populations (model 2). In the model, poor sleep 
complaints were individually put into dependent vari-
ables, and diabetic vascular complications were individu-
ally put into independent variables. We also adjusted for 
possible factors (age, gender, duration of diabetes, BMI, 
SBP, HbA1C, smoking history and dyslipidemia) in the 
regression analysis. CVD (OR 1.364, 95% CI 1.055–1.765, 
P = 0.018) was independent variable for early final awak-
ening; DKD (OR 1.322, 95% CI 1.011–1.730, P = 0.042), 
CVD (OR 1.599, 95% CI 1.239–2.063, P  =  0.000) and 
Table 2 Effect of the demographics on the poor sleep complaints
The poor sleep complaints were individually saved as dependent variable, and the demographics were saved as independent variable
Italics values are statistically significant
BMI body mass index
Demographics Difficulty fall asleep Early awake Short sleep Long sleep
OR (95% of CI) P value OR (95% of CI) P value OR (95% of CI) P value OR (95% of CI) P value
Gender 1.764 (1.350–2.307) 0.000 1.079 (0.844–1.378) 0.545 1.199 (0.943–1.523) 0.138 1.559 (0.807–3.013) 0.186
Age 1.015 (1.002–1.027) 0.020 1.045 (1.032–1.057) 0.000 1.015 (1.004–1.026) 0.006 0.965 (0.940–0.991) 0.008
BMI 0.955 (0.922–0.990) 0.012 0.997 (0.966–1.028) 0.832 1.022 (0.992–1.054) 0.153 1.029 (0.952–1.113) 0.471
Table 3 Multiple logistic regression analysis for  impact of poor sleep complaints on vascular complications in subjects 
with type 2 diabetes mellitus (model 1)
The complications of diabetes were individually put into dependent variables, poor sleep complaints were individually put into independent variables, logistic 
regression analysis was adjusted for gender, age, duration of diabetes, smoking history, BMI (body mass index), SBP (systolic blood pressure), HbA1C (glycosylated 
hemoglobin type A1c) and dyslipidemia
Italics values are statistically significant
DKD diabetic kidney disease; CVD cardiovascular disease; PAD peripheral arterial disease
Microangiopathies DKD Retinopathy Neuropathy
OR (95% of CI) P value OR (95% of CI) P value OR (95% of CI) P value
Poor sleep complaints
 Difficulty fall asleep 1.015 (0.749–1.376) 0.924 0.970 (0.726–1.296) 0.835 1.134 (0.841–1.529) 0.410
 Early wake 1.275 (0.966–1.682) 0.086 1.084 (0.831–1.413) 0.554 1.009 (0.771–1.320) 0.948
 Short sleep <6 h 1.317 (1.006–1.723) 0.045 0.774 (0.597–1.004) 0.054 1.152 (0.886–1.499) 0.291
 Long sleep >9 h 1.829 (0.893–3.746) 0.099 3.409 (1.671–6.995) 0.001 1.342 (0.636–2.828) 0.440
Macroangiopathies CVD PAD
OR (95% of CI) P value OR (95% of CI) P value
Poor sleep complaints
 Difficulty fall asleep 0.901 (0.678–1.197) 0.472 1.091 (0.803–1.483) 0.577
 Early wake 1.348 (1.042–1.745) 0.023 0.967 (0.733–1.277) 0.815
 Short sleep <6 h 1.589 (1.232–2.049) 0.000 1.343 (1.024–1.762) 0.033
 Long sleep >9 h 0.947 (0.438–1.976) 0.947 1.034 (0.466–2.294) 0.934
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PAD (OR 1.365, 95% CI 1.041–1.790, P  =  0.025) were 
independent variables for short sleep; DR (OR 3.660, 95% 
CI 1.762–7.601, P = 0.001) was independent variable for 
long sleep.
Discussion
Sleep disturbances, a condition with important for hyper-
tension, diabetes and cardiovascular disease [20–22], has 
been less researched for diabetes-associated vascular 
diseases. In addition, current studies related to sleep and 
diabetic vascular complications have focused mainly on 
OSA [15, 23–25]. Our work differs from previous studies 
by offering exploration of the association between vari-
ous poor sleep complaints and vascular complications in 
diabetes. Such research is particularly important, which 
are showing rapidly increasing prevalence of poor sleep 
complaints and diabetes in populations.
In this study, we described the effect of demograph-
ics on sleep complaints of the recruited participants. As 
expected, older patients were more likely to have these 
sleep complaints, difficulty fall asleep, early awake and 
short sleep; the female have a harder time falling asleep; 
the fatter participants were less trouble in falling asleep. 
From our data (Table 1), we found that age, gender, BMI, 
SBP, DBP, diabetes duration and HbA1C have impact on 
vascular disease distinguishably. Therefore, these factors 
were all adjusted in logistic regressions.
Interestingly, we demonstrated that early final awaken-
ing and short sleep both were risk factors for DKD from 
Chi square test. However, only short sleep persisted after 
the adjustment for a wide range of demographic and clin-
ically relevant confounders in logistic regression analysis 
(model 1). Even though sleep disturbances or OSA has 
been proved as risk factor for development and progres-
sion of DKD [15, 26], short sleep may play great role in 
pathogenesis of DKD from this research. Meanwhile, we 
found that diabetic patients with DKD had shorter sleep 
duration in logistic regression (model 2), demonstrating 
that DKD and short sleep were interrelated closely.
Our data revealed early final awakening and long sleep 
were risk factors for DR from Chi square test. But only 
long sleep still was risk factors for DR after the adjust-
ment in logistic regression (model 1). There was a litera-
ture reporting that short and long sleep was associated 
with high prevalence of DR in men and they speculated 
sleep deprivation may be involved in the pathogenesis 
of DR development [27]. In model 2, we found that DR 
patients had longer sleep; however, one report said the 
presence of diabetic retinopathy impairs the sleep quality, 
sleep latency, sleep duration and diurnal function in dia-
betic patients [17]. The proportion of participants with 
long sleep was significantly minor in the study, so we did 
not consider that long sleep was related to DR.
Tahrani et al. provided evidence that OSA is indepen-
dently associated with diabetic peripheral neuropathy 
[13]. There are literatures also reporting that pain due to 
peripheral neuropathy causes nighttime awakening and 
this leads to disturbed sleep [17, 28, 29]. But there was no 
association between poor sleep complaints and diabetic 
neuropathy from the above regression analysis.
From the previous studies, sleep disturbances and/or 
short sleep were risk factors for CVD [9, 30–32]. One 
report proposed that frequent awakenings and early 
morning awakening were not associated with a signifi-
cantly increased risk of CVD mortality in older popu-
lations [33]. Nevertheless, the prevalence of early final 
awakening was more in patients with CVD than those 
without CVD; similar was the trend with short sleep in 
this study. In the regression analysis model 1, early final 
awakening and short sleep remained independently asso-
ciated with CVD after adjustment. In addition, associa-
tion of CVD with early final awakening and short sleep 
Table 4 Multiple logistic regression analysis for  impact of vascular complications on poor sleep complaints in subjects 
with type 2 diabetes mellitus (model 2)
Poor sleep complaints were individually put into dependent variables, the complications of diabetes were individually put into independent variables, logistic 
regression analysis was adjusted for gender, age, duration of diabetes, smoking history, BMI (body mass index), SBP (systolic blood pressure), HbA1C (glycosylated 
hemoglobin type A1c) and dyslipidemia
Italics values are statistically significant
DKD diabetic kidney disease; CVD cardiovascular disease; PAD peripheral arterial disease
Variables Difficulty fall asleep Early wake Short sleep Long sleep
OR (95% of CI) P value OR (95% of CI) P value OR (95% of CI) P value OR (95% of CI) P value
DKD 1.052 (0.778–1.422) 0.741 1.300 (0.986–1.713) 0.063 1.322 (1.011–1.730) 0.042 1.892 (0.945–3.788) 0.072
Retinopathy 0.983 (0.738–1.310) 0.909 1.073 (0.822–1.399) 0.605 0.780 (0.601–1.011) 0.061 3.660 (1.762–7.601) 0.001
Neuropathy 1.149 (0.854–1.545) 0.359 1.022 (0.782–1.338) 0.871 1.160 (0.893–1.509) 0.267 1.511 (0.694–3.289) 0.298
CVD 0.896 (0.675–1.190) 0.450 1.364 (1.055–1.765) 0.018 1.599 (1.239–2.063) 0.000 1.008 (0.486–2.089) 0.948
PAD 1.110 (0.816–1.509) 0.507 0.982 (0.746–1.294) 0.899 1.365 (1.041–1.790) 0.025 1.063 (0.478–2.361) 0.881
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was showed in the model 2, which have not been reported 
in diabetes patients to the best of our knowledge.
We tried to assess the association between poor sleep 
complaints with lower extremity PAD in the type 2 dia-
betes patients. There was great difference between the 
patients with and without PAD in the prevalence of early 
final wakening and short sleep from Chi square test. In 
the model 1, only short sleep was risk factor for PAD after 
the adjustment. Diabetic patients with PAD had shorter 
sleep duration in logistic regression model 2 after adjust-
ment. Even though a few current literatures revealed that 
prevalence of OSA is high in patients with PAD [34, 35], 
there is little literature reporting the association between 
poor sleep complaints and PAD.
Mechanisms of poor sleep complaints impacting mor-
bidity of diabetic vascular complications have been 
speculated. Pathogenesis of vascular diseases in diabe-
tes ascribe to oxidative stress, low-grade inflammation, 
endothelial dysfunction and so on [36]. First, poor sleep 
complaints could activate the autonomic nervous sys-
tem and elevate the secretion of catecholamine, which 
can stimulate production of inflammatory mediators and 
could lead to metabolic imbalance [37]. Second, sleep 
disturbances and sleep fragmentation could activate pro-
inflammatory transcription factors such as nuclear factor 
kappa B (NF-κ B), which is a key player in inflamma-
tory and innate immune responses and a master regula-
tor of inflammatory gene expression, and genes such as 
TNF-α or IL-8 that are important to the atherosclerotic 
process. Sleep disturbances may also aggravate oxidative 
stress which could sharpen endothelial dysfunction and 
increase insulin resistance [38].
The strength of this study was that it is the first time 
to assess the relationship between diabetic complications 
and poor sleep complaints using validated questionnaire 
roundly. Secondly, the studied-population was large and 
representative, so the results were worthy to be trusted 
and extrapolated. However, some limitations of this study 
should be taken attention. First, the adjusted-confound-
ers were identical in the regression analysis, and this may 
lead to inaccurate adjustment for each diabetic complica-
tion. Second, it is difficult to draw an exact causal rela-
tionship between complications of diabetes and poor 
sleep complaints due to cross-sectional design of the 
study. In addition, some sleep complaints such as daytime 
sleepiness and frequent awakening were not assessed in 
the study, and we should perfect it in future study.
Conclusions
Poor sleep complaints were distinguishably associ-
ated with diabetic vascular complications. Larger 
prospective trails using the objective assessment by 
polysomnography are warranted to investigate the 
underlying mechanisms. Clinicians should pay more 
attention to poor sleep complaints for improving diabe-
tes patients life quality.
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